Pharmacokinetic effects and safety of olaparib administered with endocrine therapy: A phase I study in patients with advanced solid tumours.
De Vos, F
De Grève, J
Dean, Emma J
AffiliationNorthern Centre for Cancer Care, Newcastle University, Newcastle upon Tyne, UK.
MetadataShow full item record
AbstractThe PARP inhibitor olaparib is efficacious as monotherapy and has potential application in combination with endocrine therapy for the treatment of breast cancer. This phase I study assessed the safety and pharmacokinetic (PK) profiles of olaparib combined with tamoxifen, anastrozole or letrozole in patients with advanced solid tumours.
CitationPharmacokinetic effects and safety of olaparib administered with endocrine therapy: A phase I study in patients with advanced solid tumours. 2018, 35 (11):1945-1964 Adv Ther
JournalAdvances in Therapy